Show simple item record

dc.contributor.authorBanerjee, Yajnavalka
dc.date.accessioned2022-03-15T08:54:29Z
dc.date.available2022-03-15T08:54:29Z
dc.date.issued2021
dc.identifier.other204-2021.156
dc.identifier.urihttps://repository.mbru.ac.ae/handle/1/890
dc.description.abstractIntroduction: A number of anti-diabetic treatments have been favored during the continuing spread of the current SARS-CoV-2 pandemic. Glucagon like peptide-1 receptor agonists (GLP1-RAs) are a group of antidiabetic drugs, the glucose reducing effect of which is founded on augmenting glucose-dependent insulin secretion with concomitant reduction of glucagon secretion and delayed gastric emptying. Apart from their glucose lowering effects, GLP1-RAs also exert a plethora of pleiotropic activities in the form of anti-inflammatory, anti-thrombotic and anti-obesogenic properties, with beneficial cardiovascular and renal impact. All these make this class of drugs a preferred option for managing patients with type 2 diabetes (T2D), and potentially helpful in those with SARS-CoV2 infection. Areas covered: In the present article we propose a hypothetical molecular mechanism by which GLP1- RAs may interact with SARS–CoV-2 activity. Expert Opinion: The beneficial properties of GLP1-RAs may be of specific importance during COVID-19 infection for the most fragile patients with chronic comorbid conditions such as T2D, and those at higher cardiovascular and renal disease risk. Yet, further studies are needed to confirm our hypothesis and preliminary findings available in the literature.en_US
dc.language.isoenen_US
dc.subjectSARS-CoV-2en_US
dc.subjectCOVID-19en_US
dc.subjectGLP1RAen_US
dc.subjectCoronavirusen_US
dc.subjectPandemicen_US
dc.subjectDiabetesen_US
dc.subjectTherapyen_US
dc.titleThe role of GLP-1 receptor agonists during COVID-19 pandemia: a hypothetical molecular mechanismen_US
dc.typeArticleen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record